Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer
Jada G. Hamilton(Memorial Sloan Kettering Cancer Center), Susan M. Domchek(University of Pennsylvania), Elizabeth Schofield(Memorial Sloan Kettering Cancer Center), Stacy Pundock(University of Pennsylvania), Heather Symecko(University of Pennsylvania), Erin Salo‐Mullen(Memorial Sloan Kettering Cancer Center), Kelsey Breen(Memorial Sloan Kettering Cancer Center), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Ibrahim H. Shah(Memorial Sloan Kettering Cancer Center), Karen A. Cadoo(Memorial Sloan Kettering Cancer Center), Rebecca Gebert(Memorial Sloan Kettering Cancer Center), Kelsey Spielman(University of Pennsylvania), Magan Trottier(Memorial Sloan Kettering Cancer Center), Vivek Narayan(University of Pennsylvania), Maria I. Carlo(Memorial Sloan Kettering Cancer Center), Zsofia K. Stadler(Memorial Sloan Kettering Cancer Center), Amanda Catchings(Memorial Sloan Kettering Cancer Center), Rebecca Mueller(University of Pennsylvania), A. B. Arutyunova(University of Pennsylvania), Kim A. Reiss(University of Pennsylvania), Melissa Batson(University of Pennsylvania), Kenneth Offit(Memorial Sloan Kettering Cancer Center)
Cited by 73
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2021|1.1k